Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029572 | 0.87 | KDM4E (0.65) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10029587 | 0.85 | LMNA (0.59) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10029565 | 0.84 | KDM4E (0.61) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL629896 | 0.82 | LMNA (0.65) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10029581 | 0.82 | KDM4E (0.81) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL25410911 | 0.81 | LMNA (0.73) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9555570 | 0.81 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL628118 | 0.81 | LMNA (0.60) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10029557 | 0.79 | KDM4E (0.60) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| Fenclozic Acid SCHEMBL27104 | 0.79 | LMNA (0.73) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | RBP4, RBP1, FABP4 | LMNA 1913/4885KDM4E 751/4885SMN1; SMN2 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.